Effect of a PPAR-Alpha Agonist on the Age Related Changes in Myocardial Metabolism and Mechanical Function

Status unconfirmed · Not applicable

Conditions studied: Cardiovascular Diseases

In brief

The purpose of this study is to determine if treatment with a drug called fenofibrate, which is a PPAR-alpha agonist and controls how the heart metabolizes fats, will reverse the age-related decline in cardiac fat metabolism and mechanical function.

Key facts

Study ID

NCT00627653

Run by

National Institute on Aging (NIA)

People needed

60

Starts

2005-10-01

Expected to finish

2009-12-01

Last updated by the study team

2009-02-19

Who can join

Age: 21 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Aged 60-75 or 21-35
• Normal glucose tolerance test
• Normal plasma fasting lipid panel (fasting total cholesterol less than 220 mg/dL)
• Normal rest/stress echocardiogram
• BMI (body mass index) less than 30 kg/m2
• Must be sedentary (active, but do not engage in regular exercise or jobs that require strenuous exertion)

You may not qualify if…

• Coronary artery disease
• High blood pressure
• Current smoker
• Diabetes mellitus
• Cardiovascular disease (signs and symptoms of any kind)
• Pregnant or breastfeeding

Where it is running

• Washington University School of Medicine — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.